HCWB (HCW Biologics) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $1.04
GF Value $7.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Tariff Resilience Score?

HCW Biologics HCWB -7.62% 39 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,376 Biotechnology companies, HCW Biologics ranks better than 90.41% on this metric.

HCW Biologics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

HCW Biologics has HCWB operates in the biotech sector, which is less affected by tariffs. Its supply chain is more localized, and it benefits from industry-specific exemptions. However, any international expansion could introduce some tariff risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes HCW Biologics might have Highly Resilient.

HCW Biologics  (NAS:HCWB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

HCW Biologics Tariff Resilience Score Related Terms

HCWB vs MTVA, INTI, HOOK: Tariff Resilience Score Comparison

For the Biotechnology subindustry, HCW Biologics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Tariff Resilience Score falls into.


HCWB
39GF Score
HCW Biologics Inc HCWB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
HCW Biologics (HCWB) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, HCW Biologics ranks #132 out of 1376 companies in the Biotechnology industry, placing it in the top 9.6%.
Is HCW Biologics' Tariff Resilience Score too high?
HCW Biologics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. HCW Biologics' value of 7 is 75% above this industry median. Based on the distribution chart, HCW Biologics ranks #132 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Tariff Resilience Score compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #132 out of 1376 companies for Tariff Resilience Score. This places HCW Biologics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. HCW Biologics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.04 — trading 85.7% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $1.04 is trading 85.7% below its estimated GF Value™ of $7.29. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Tariff Resilience Score: 7
  • GF Value™: $7.29 vs. price of $1.04 (85.7% below fair value)
  • GF Score™: 39/100 with 7 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1376)

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price
$7.29
GF Value